The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

NCT03162562 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision to discontinue long-term follow-up

Conditions

Cancer of Ovary
Neoplasms, Ovarian
Ovarian Cancer Stage IV
Ovarian Cancer Recurrent
Ovarian Cancer Stage III
Ovary Cancer

Interventions

BIOLOGICAL: Oregovomab
DRUG: Poly ICLC

Sponsor

CanariaBio Inc.